BAM Associate Editor Prof. Kelvin Yeung develops novel nerve-osteogenic peptide for bone regeneration and osteoporosis therapy

Published 20 November, 2026

A research team led by Prof. Kelvin Wai Kwok Yeung, Associate Editor of Bioactive Materials and Ng Chun-Man Professor in Orthopaedic Bioengineering at The University of Hong Kong (HKU), has developed a novel nerve-osteogenic peptide that promotes bone regeneration and neural modulation simultaneously. The work, which harnesses nerve-to-bone crosstalk, was awarded a Gold Medal at the 51st International Exhibition of Inventions of Geneva.

The Gold Medal diploma and the NeurOssence Bio Limited booth at the 51st International Exhibition of Inventions of Geneva. Image courtesy of HKUMed.

Rethinking the nerve-bone connection

As populations age, bone-related conditions such as osteoporosis are becoming an increasingly pressing public health concern, with progressive bone loss raising fracture risk and undermining mobility and quality of life. Recent evidence points to a complex, bidirectional communication network between the nervous system and bone. Beyond sensory and motor control, the nervous system contributes to bone metabolism through neuroendocrine signals and neurochemical factors, influencing bone formation, repair and remodelling. This view challenges the traditional understanding of bone as an isolated tissue.

Building on this concept, the team designed a nerve-osteogenic peptide that acts on nerve-bone signalling pathways to support bone and neural function in parallel. In mouse models of osteoporosis, the peptide exerted a significant effect during weeks 4 to 8 of disease progression, helping preserve bone mass and trabecular microstructure.

Schematic illustration of the integrated neuro-osteogenic technology platform. Image courtesy of the research team.

Dual action: more bone formation, less bone loss

Current osteoporosis therapies fall into two main categories: anabolic agents that promote bone formation and antiresorptive agents that suppress bone resorption. Both are effective, but each acts through a relatively narrow mechanism. By contrast, the new peptide stimulates osteoblast activity while inhibiting osteoclast formation, achieving a dual effect of increasing bone formation and reducing bone loss.

It also accelerates mineralisation and promotes type I collagen synthesis, producing a more robust bone microstructure. The team uses a building analogy: bone mineral is the brick, while collagen provides the steel framework, and the peptide strengthens both at once. Emerging data further suggest that the platform supports neuronal differentiation and nerve repair, opening possibilities in fracture healing, nerve injury repair and broader regenerative medicine.

Prof. Kelvin Yeung (right) presenting the research at the 51st International Exhibition of Inventions of Geneva. Image courtesy of HKUMed.

Engineering stability and confirming safety

A long-standing limitation of peptide therapeutics is rapid enzymatic degradation, which shortens their active lifetime in the body. The team modified the peptide's molecular structure using new synthesis and modification technologies, substantially improving its stability and tolerability. Testing showed that the peptide remains stable in serum and acidic environments, reducing the risk of premature breakdown and improving its potential for clinical use.

Preliminary acute toxicity and cytotoxicity studies found no obvious adverse effects on stem cells, neurons or immune cells. Animal studies likewise revealed no significant toxicity or adverse reactions in major organs, including the liver, heart, lungs, spleen and brain. Notably, the peptide showed no sign of triggering an immune response; instead, it increased the population of M2-type immune cells associated with tissue repair, further supporting regeneration.

The peptide increases bone formation while reducing bone loss, and supports neural repair through nerve-bone crosstalk.

From treatment to prevention

Beyond osteoporosis therapy, the team is developing oral peptide bone supplements in tablet and capsule formats. The aim is to serve patients with osteopenia and osteoporosis, and potentially wider groups with bone health needs, including older adults, people with limited physical activity, pregnant women and children. The team stresses that final dosage and indications will require confirmation through clinical studies and regulatory approval.

Translation and clinical development

To accelerate translation, the team founded the start-up NeurOssence Bio Limited in early 2026, with support from HKU and the Innovation and Technology Commission. The project has obtained ethical approval for human research and is applying to Queen Mary Hospital for a Phase I/IIA clinical trial to evaluate the safety and bone-forming effects of the nerve-osteogenic peptide in humans.

Prof. Yeung said that further validation of nerve-to-bone crosstalk as a therapeutic target could lead to a new treatment model combining neural modulation with bone regeneration, with implications for osteoporosis, fracture repair and regenerative medicine. Bioactive Materials will continue to follow developments in this area.

Back to News from Bioactive Materials

Stay Informed

Register your interest and receive email alerts tailored to your needs. Sign up below.